Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2006

01-08-2006 | Original Article

Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users

Published in: Osteoporosis International | Issue 8/2006

Login to get access

Abstract

Introduction

Despite the efficacy of bisphosphonates to reduce fractures in high risk populations, bisphosphonate adherence among chronic glucocorticoid users has received limited attention. Moreover, perceived differences in GI tolerability may lead physicians to preferentially prescribe particular bisphosphonates.

Methods

Among chronic glucocorticoid users (>60 days of therapy) enrolled in managed care, we identified individuals initiating therapy with alendronate or risedronate during 2001–2004. Multivariable logistic regression and proportional hazards models were used to examine factors associated with channeling patients to risedronate (versus alendronate) and with discontinuation (>3-month gap without refill). The Medication Possession Ratio (MPR) was calculated as the filled days of medication divided by the interval of time between prescriptions.

Results

Of 1,158 glucocorticoid users initiating bisphosphonate therapy, demographic characteristics of alendronate users (n=754) and risedronate users (n=404) were similar for age (mean 53 years) and gender (approximately 80% female). Past history of a GI symptom or event was associated with risedronate receipt (OR=2.24, 95% CI 1.15–4.35). After multivariable adjustment, rates of discontinuation (mean time to discontinuation approximately 18 months) and adherence (mean MPR=73%) were similar between users of the two bisphosphonates. Younger age, greater medical comorbidity, and lack of BMD testing were significantly associated with discontinuation.

Conclusions

Overall persistence rates were suboptimal for bisphosphonate use among chronic glucocorticoids users and did not differ significantly by drug. Newer strategies to promote long-term adherence are needed to improve osteoporosis therapeutic effectiveness.
Appendix
Available only for authorised users
Literature
1.
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRef
2.
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352PubMedCrossRef
3.
Tosteson AN, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115(3):209–216CrossRefPubMed
4.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15(12):1003–1008CrossRefPubMed
5.
Schnitzer T, Bone H, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group. Aging 12(1):1–12PubMed
6.
Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119(3):631–638CrossRefPubMed
7.
Kane S, Borisov N, Brixner D (2004) Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Managed Care 10:S216–S226
8.
Miller R, Bolognese M, Worley K, Solis A, Sheer R (2004) Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Am Journal of Managed Care. 10:S207–S215
9.
Rizzo JA, Simons WR (1997) Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 19(6):1446–1457; Discussion 1424–1425CrossRefPubMed
10.
Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd ed. Wiley, New York
11.
Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899PubMedCrossRef
12.
Curtis JR, Westfall AO, Allison JJ et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52(8):2485–2494CrossRefPubMed
13.
Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7(6):597–605PubMed
14.
Yood RA, Harrold LR, Fish L et al (2001) Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 161:1322–1327CrossRefPubMed
15.
Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRefPubMed
16.
Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80(7):856–861PubMedCrossRef
17.
Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460CrossRefPubMed
18.
Ettinger M, Gallagher R, Amonkar M, Smith J, MacCosbe PE (2004) Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 50(9S):S513–S514
19.
Papaioannou A, Ioannidis G, Adachi J et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:S808–S813CrossRef
20.
Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26(2):245–256PubMedCrossRef
21.
22.
Pickney CS, Arnason JA (2005) Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16(9):1156–1160CrossRefPubMed
23.
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123CrossRefPubMed
24.
Curtis J, Westfall A, Allison J, Freeman A, Kovac S, Saag K (2006) Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Safety (in press)
25.
Schneeweiss S, Glynn RJ, Avorn J, Solomon DH (2005) A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 58(1):98–102CrossRefPubMed
26.
Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J (2003) Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 115(9):715–720CrossRefPubMed
27.
Haugeberg G, Griffiths B, Sokoll KB, Emery P (2004) Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 63(8):940–944CrossRefPubMed
28.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503CrossRef
29.
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14(3):259–262PubMed
30.
Miller PD, Woodson G, Licata AA et al (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22(12):1433–1442CrossRefPubMed
31.
Lemeshow S, Hosmer JDW (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115:92–106PubMed
32.
Hosmer JDW, Lemeshow S (1999) Applied survival analysis: Regression modeling of time to event data. Wiley Series in Probability and Statistics: John Wiley and Sons
Metadata
Title
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users
Publication date
01-08-2006
Published in
Osteoporosis International / Issue 8/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0136-8

Other articles of this Issue 8/2006

Osteoporosis International 8/2006 Go to the issue

Original Article

Dietary determinants of post-menopausal bone loss at the lumbar spine: a possible beneficial effect of iron

Original Article

Vitamin D receptor genotype and risk of osteoporotic hip fracture in elderly women of Utah: an effect modified by parity

Original Article

Long-term recreational gymnastics provides a clear benefit in age-related functional decline and bone loss. A prospective 6-year study

Original Article

Epidemiology of hip fracture in Iran: results from the Iranian Multicenter Study on Accidental Injuries

Letter

Influence of corticosteroids on QUS parameters of the calcaneus in the 1st year after renal transplantation: authors’ reply to Dr. Adamczyk

Original Article

Lifetime sport and leisure activity participation is associated with greater bone size, quality and strength in older men